NCT01068782View on ClinicalTrials.gov

Study of Multiple Doses and Regimens of XL184 (Cabozantinib) in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

PHASE2CompletedINTERVENTIONAL

Enrollment

19

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

May 31, 2011

Study Completion Date

October 31, 2013

Conditions

Astrocytic Tumors

Interventions

DRUG

XL184

given orally as capsules

Trial Locations (19)

14226

Amhearst

14642

Rochester

17033

Hershey

22908

Charlottesville

35294

Birmingham

44195

Cleveland

48202

Detroit

55407

Minneapolis

60611

Chicago

60637

Chicago

75246

Dallas

75426

Dallas

78229

San Antonio

92024

Encinitas

94523

Pleasant Hill

98122

Seattle

02115

Boston

Unknown

Calgary

Montreal

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Exelixis

INDUSTRY